Yuki Mukai1,2, Stefan Janssen1, Christoph Glanzmann1,3, David Holzmann4, Gabriela Studer5,6. 1. Department of Radiation Oncology, Head Neck Cancer Center, University Hospital Zurich, Rämistr. 100, 8091, Zurich, Switzerland. 2. Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 3. Institute for Radiation Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland. 4. Department of Otorhinolaryngology, Head and Neck Surgery, Head Neck Cancer Center, University Hospital Zurich, Zurich, Switzerland. 5. Department of Radiation Oncology, Head Neck Cancer Center, University Hospital Zurich, Rämistr. 100, 8091, Zurich, Switzerland. Gabriela.Studer@usz.ch. 6. Institute for Radiation Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland. Gabriela.Studer@usz.ch.
Abstract
OBJECTIVE: This study aims to evaluate local control and intermediate-term cosmetic outcome in patients with cancer of the nose treated with intensity-modulated radiotherapy (IMRT). METHODS: From June 2008 to September 2015, 36 consecutive patients presenting with nasal cavity, ala of the nose, or nasal vestibule tumors were treated at the Department of Radiation Oncology, University Hospital Zurich either postoperatively (n = 14; 3/14 with nasal ablation) or with definitive IMRT (n = 22). Of these 36 patients, 8 presented with recurrent disease after surgery only and 1/36 with N1 disease. Concurrent systemic therapy was administered in 18/36 patients (50%). Nasal follow-up (FU) imaging documentation of 13 patients with preserved organ and >6 months FU offers a pre/post IMRT FU comparison. In addition, these patients' subjective evaluation of cosmesis was assessed. RESULTS: Mean/median FU was 41/33 months (range 5-92 months). Salvage ablation with curative intent was undergone by 3 patients with local relapse after definitive (n = 2) and postoperative (n = 1) IMRT. The 3‑year local control, ultimate local control, and overall survival rates were 90, 97, and 90 %, respectively. Subjective and objective cosmetic outcome after IMRT is very satisfying so far. CONCLUSION: IMRT for nasal tumors was found to be effective and well tolerated. Intermediate-term cosmetic results are good. Radical surgical procedures may be saved for curative salvage treatment.
OBJECTIVE: This study aims to evaluate local control and intermediate-term cosmetic outcome in patients with cancer of the nose treated with intensity-modulated radiotherapy (IMRT). METHODS: From June 2008 to September 2015, 36 consecutive patients presenting with nasal cavity, ala of the nose, or nasal vestibule tumors were treated at the Department of Radiation Oncology, University Hospital Zurich either postoperatively (n = 14; 3/14 with nasal ablation) or with definitive IMRT (n = 22). Of these 36 patients, 8 presented with recurrent disease after surgery only and 1/36 with N1 disease. Concurrent systemic therapy was administered in 18/36 patients (50%). Nasal follow-up (FU) imaging documentation of 13 patients with preserved organ and >6 months FU offers a pre/post IMRT FU comparison. In addition, these patients' subjective evaluation of cosmesis was assessed. RESULTS: Mean/median FU was 41/33 months (range 5-92 months). Salvage ablation with curative intent was undergone by 3 patients with local relapse after definitive (n = 2) and postoperative (n = 1) IMRT. The 3‑year local control, ultimate local control, and overall survival rates were 90, 97, and 90 %, respectively. Subjective and objective cosmetic outcome after IMRT is very satisfying so far. CONCLUSION: IMRT for nasal tumors was found to be effective and well tolerated. Intermediate-term cosmetic results are good. Radical surgical procedures may be saved for curative salvage treatment.
Entities:
Keywords:
IMRT and nose; Toxicity; cosmesis; nasal tumors; treatment tolerance
Authors: Johannes A Langendijk; Robert Poorter; Christiaan R Leemans; Remco de Bree; Patricia Doornaert; Berend J Slotman Journal: Int J Radiat Oncol Biol Phys Date: 2004-08-01 Impact factor: 7.038
Authors: Justin Wray; Christopher G Morris; Jessica M Kirwan; Robert J Amdur; John W Werning; Peter T Dziegielewski; William M Mendenhall Journal: Eur Arch Otorhinolaryngol Date: 2015-03-13 Impact factor: 2.503
Authors: J J Mazeron; D Chassagne; J Crook; F Bachelot; F Brochet; D Brune; F Brunin; U Bunescu; N Daly; S Danczak Journal: Radiother Oncol Date: 1988-11 Impact factor: 6.280
Authors: Christina Leitzen; Timo Wilhelm-Buchstab; Thomas Müdder; Martina Heimann; David Koch; Christopher Schmeel; Birgit Simon; Sabina Stumpf; Susanne Vornholt; Stephan Garbe; Fred Röhner; Felix Schoroth; Hans Heinz Schild; Heinrich Schüller Journal: Strahlenther Onkol Date: 2018-01-25 Impact factor: 3.621